Top Markets
Coin of the day
D. Western Therapeutics Institute, Inc. D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc.

4576
Rank in Stocks #27584
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused... D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
Share Price
$0.56109583
Market Cap
$32.25M
Change (1 day)
2.38%
Change (1 year)
-24.84%
Country
JP
Trade D. Western Therapeutics Institute, Inc. (4576)

Category

Revenue for D. Western Therapeutics Institute, Inc. (4576)
Revenue in Aug 2026 TTM: 0
According to D. Western Therapeutics Institute, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for D. Western Therapeutics Institute, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$2.23B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH